Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Lixia Ju
    Mingquan Han
    Jinmei Su
    Chunyan Wu
    Zhengwei Dong
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 561 - 564
  • [22] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Ju, Lixia
    Han, Mingquan
    Su, Jinmei
    Wu, Chunyan
    Dong, Zhengwei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 561 - 564
  • [23] A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib
    Kunte, Siddharth
    Stevenson, James
    CLINICAL LUNG CANCER, 2021, 22 (03) : E298 - E300
  • [24] Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report
    Zhao, Shikang
    Zhu, Shuai
    Lei, Xi
    Xu, Dongbo
    Shi, Tao
    Chen, Qiusong
    Ren, Fan
    Chen, Gang
    Huang, Dingzhi
    Xu, Song
    THORACIC CANCER, 2021, 12 (20) : 2815 - 2818
  • [25] Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis A Case Report
    Wang, Wenxian
    Wu, Wei
    Zhang, Yiping
    MEDICINE, 2016, 95 (30)
  • [26] Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
    Gao, Peng
    Tang, Kangning
    Hao, Yuqiu
    Li, Wei
    Lv, Xuejiao
    Li, Dapeng
    Jia, Yuxi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation A case report
    Qin, Ruo-Yan
    Liu, Ling-Shuang
    Zhang, Hui-Yong
    Lu, Cheng-Hua
    Guo, Xiao-Yan
    Zhang, Ling-Yue
    Yuan, Xin-Bei
    Xue, Hong-Hao
    MEDICINE, 2021, 100 (04)
  • [28] The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
    Kim, H. R.
    Lim, S. M.
    Kim, H. J.
    Hwang, S. K.
    Park, J. K.
    Shin, E.
    Bae, M. K.
    Ou, S. -H. I.
    Wang, J.
    Jewell, S. S.
    Kang, D. R.
    Soo, R. A.
    Haack, H.
    Kim, J. H.
    Shim, H. S.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2364 - 2370
  • [29] Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: A case report
    Takakuwa, Osamu
    Oguri, Tetsuya
    Yokoyama, Midori
    Hijikata, Hisatoshi
    Uemura, Takehiro
    Ohkubo, Hirotsugu
    Maeno, Ken
    Niimi, Akio
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 121 - 123
  • [30] Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report
    Zhang, Na
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Xie, Zhi
    Wang, Bin-Chao
    Tu, Hai-Yan
    Jiang, Ben-Yuan
    Wu, Yi-Long
    ONCOLOGY LETTERS, 2014, 8 (06) : 2624 - 2626
12345